Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2476 to 2490 of 9128 results

  1. Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

    In development Reference number: GID-TA11638 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer ID6573

    In development Reference number: GID-TA11755 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    In development Reference number: GID-TA11743 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  4. Unilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor

    In development Reference number: GID-HTG10859 Expected publication date:  17 December 2026

    HealthTech guidance
    In development

  5. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]

    Awaiting development Reference number: GID-TA11657 Expected publication date:  07 April 2027

    Technology appraisal guidance
    Awaiting development

  6. Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]

    In development Reference number: GID-TA11858 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    In development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management

    In development Reference number: GID-NG10435 Expected publication date:  16 February 2027

    NICE guideline
    In development

  9. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  10. Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]

    Awaiting development Reference number: GID-TA11973 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Enlicitide decanoate for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6656]

    Awaiting development Reference number: GID-TA11871 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  13. Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [ID6760]

    Awaiting development Reference number: GID-TA11975 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716

    In development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development